GlassScriptPhysician profile
Stanislav Ozhog
NPI 1033579867
$1,056.83
in general payments reported to CMS, 2019-2025
13 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $286 · 2023: $160 · 2024: $201 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745 · Education: $25.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.45 |
| Education | $25.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $188.50 | 2024-2025 | Tavneos |
| Nxstage Medical, INC. | $122.17 | 2024-2025 | Liberty Select Cycler, Nxstage System One |
| Aurinia Pharma U.S., INC. | $117.93 | 2022 | |
| Bard Peripheral Vascular, INC. | $103.53 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.32 | 2022-2023 | |
| Calliditas Therapeutics US INC. | $95.31 | 2024-2025 | Tarpeyo |
| Genzyme Corporation | $92.23 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $57.91 | 2022-2023 | Jynarque |
| Akebia Therapeutics INC | $49.44 | 2024-2025 | Auryxia, Vafseo |
| Novo Nordisk INC | $40.76 | 2023-2025 | Ozempic, Rybelsus |
| Fresenius USA Marketing, INC. | $37.35 | 2025 | Velphoro |
| Travere Therapeutics, INC. | $36.59 | 2023-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $13.79 | 2023 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanislav Ozhog listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.